阿斯利康和第一三共的德曲妥珠单抗(Enhertu)在III期临床试验中显示,联合帕妥珠单抗一线治疗HER2阳性转移性乳腺癌,相比标准治疗显著改善无进展生存期,且总生存期早期趋势更优。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.